Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted ...

Roche has joined its Big Pharma peers in the emerging degrader-antibody conjugate (DAC) space, paying C4 Therapeutics $20 ...

Financially, the agreement includes a $20 million upfront payment to C4 Therapeutics, with the potential for additional ...

C4 Therapeutics (CCCC) stock is in focus as the company is in pact with Roche (RHHBY) for degrader-antibody conjugates, a new ...

C4 Therapeutics said on Thursday it has entered into a deal ​focused on research and development of ‌a type of cancer drug ...

Posters plastering the room, a persistent, vivacious chatter — at the March New England Science Symposium, what might have seemed like a tornado of unrelated ideas and academic entropy were actually ...

KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise of KT-200 triggers a $45 million milestone ...

Investing.com -- C4 Therapeutics (NASDAQ:CCCC) shares rose 10% after the company announced an expanded collaboration with Roche (SIX:RO, ROP; OTCQX:RHHBY) to develop degrader-antibody conjugates for ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences WATERTOWN, Mass.

Shares of C4 Therapeutics, Inc. (CCCC) jumped 5% higher in pre-market trading on Thursday, after the company expanded its partnership with Swiss pharmaceutical company Roche to develop cancer ...

Gilead has tucked another drug candidate into a pipeline bulging from a recent deal flurry, paying $45 million to exercise ...